Axim Biotechnologies Inc (AXIM)

[BesaoT35]

In the interview CEO JH said that he surmised that the FDA did not want patients and doctors to see precisely with the test that their antibody levels for Covid drop fast after the vaccine administrations. I thought that was interesting to hear about.

The stock price was 80 cents to $1.00 a few years ago when stockholders were hoping for the roll out of the Covid antibody level tests. We are now at a low of 1 cent for a few trades today.

He said that our dry eye disease tests are worth around 10X our current market cap. That does not include the Parkinson’s Disease test which seems like to me it would have a large market. There are likely other interesting tests that Sapphire is researching.

He mentioned the CLIA Waiver time for approval at the FDA is now targeted for 90 days and not the previous 8 or 9 months. That is good to hear about.

The stock chart shows a very dim prospect for this company but in actuality there are good reasons in my view to foresee and hope for a reasonable chance of success with AXIM.

Is it naive for me to feel this way? Maybe someone should describe here the probable likelihood of the reverse split risk in the near future. Then there are the subsequent offerings dilution risks.

There are other sometimes overlooked pitfalls of buying pre revenue small cap biotech companies. The tactics of shorts and toxic convertible debt schemes are also considerations.

Thanks.